Ropinirole in the Treatment of Patients With Restless Legs Syndrome: A US-Based Randomized,Double-Blind,Placebo-Controlled Clinical Trial
- Treatment of Restless Legs Syndrome. Comella, Cynthia // Neurotherapeutics;Jan2014, Vol. 11 Issue 1, p177
Restless legs syndrome (RLS) is a common disorder diagnosed by the clinical characteristics of restlessness in the legs associated often with abnormal sensations that start at rest and are improved by activity, occurring with a diurnal pattern of worsened symptoms at night and improvement in the...
- Ropinirole in the Treatment of Restless Legs Syndrome. Vetrugno, Roberto; Montagna, Pasquale // Clinical Medicine: Therapeutics;2009, Issue 1, p1237
Restless Legs Syndrome (RLS) is a neurological disorder characterized by unpleasant sensations in the legs and an irresistible urge to move them to relieve discomfort. Evidence-based guidelines consider dopaminergic therapy to be the mainstay of treatment for RLS. Ropinirole is a modern,...
- Ropinirole. // AHFS Consumer Medication Information;Jan2017, p1
Ropinirole is used alone or with other medications to treat the symptoms of Parkinson's disease (PD; a disorder of the nervous system that causes difficulties with movement, muscle control, and balance), including shaking of parts of the body, stiffness, slowed movements, and problems with...
- how can I calm trembling legs? // Natural Health;Jun2006, Vol. 36 Issue 6, p24
The article presents views of various medical personnel on symptoms and treatment options for restless legs syndrome (RLS). Mark Hallett, senior investigator for the National Institute of Neurological Disorders and Stroke, says that one way to treat the condition is with dopamine...
- Symptomatic treatment of restless legs syndrome. Davis, Kelli; Saunders, Carol S. // Patient Care;Jun2002, Vol. 36 Issue 8, p10
Discusses the efficacy of pramipexole, a dopamine receptor agonist, in treating restless legs syndrome (RLS). Information on RLS; Treatment of RLS; Studies showing the efficacy of pramipexole in treating RLS.
- Distressing sensations. Mason, Mary-Claire // Nursing Standard;4/20/2011, Vol. 25 Issue 33, p23
A little-understood condition needs to be taken seriously as its effects can range from irritating to disabling. Mary-Claire Mason reports.
- GSK wins restless leg race. Iskowitz, Marc // Medical Marketing & Media;Jun2005, Vol. 40 Issue 6, p14
This article reports that GlaxoSmithKline PLC's Requip has become the first drug to win the U.S. Food and Drug Administration's approval to treat restless legs syndrome (RLS). Already on the market to treat the symptoms of Parkinson's disease, Requip won approval at lower doses for treating...
- IRLSSG releases guidelines for restless legs syndrome. // PharmacoEconomics & Outcomes News;8/1/2013, Issue 684, p3
The article reports on the guidelines for the long-term treatment of restless legs syndrome from the International Restless Legs Syndrome Study Group (IRLSSG) which recommends the use of either a dopamine-receptor agonist as first-line treatments of the disease.
- Gabapentin improved sensory and motor symptoms in the restless legs syndrome. Albanese, Alberto; Filippini, Graziella // ACP Journal Club;Jul/Aug2003, Vol. 139 Issue 1, p17
Examines whether gabapentin is more effective than placebo for improving sensory and motor symptoms in patients with the restless legs syndrome (RLS). Main outcome measures; Assessment of clinically relevant outcomes of new drug treatments; Risk for carryover effect.